Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
SBI steps in with $1-billion funding for Sun Pharma’s Organon deal
The size of SBI’s funding for the $12-billion Sun Pharma-Organon deal underscores the growing appetite among state-run banks to back M&A deals by Indian companies.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Sun Pharma, Ozempic Defy Slowdown In India's Weight-Loss Market
The slowdown is largely attributed to a natural cooling after the rapid patient onboarding seen in April. With a significant portion of early adopters already initiated on therapy, repeat purchases are now emerging as the primary growth driver for the category.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint
Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Sun Pharmaceutical Industries Ltd drops for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
Nifty trades below 23,400 level; European mrkt decline
Consumer durables, realty and pharma shares advanced while metal, private bank and IT shares declined.
BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
Neha Manpuria, Senior Analyst - Pharma, Healthcare at BofA Global Research, says semaglutide launches could emerge as a key growth driver for Indian pharma companies in FY27.
Market trade near day's high; European mrkt advance
IT, consumer durables and auto shares advanced while pharma, media and oil & gas shares declined.
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.